Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study
Fiche du document
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1093/annonc/mdi154
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/15817597
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/0923-7534
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_2C2ACD8CD0E91
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
Therapy Colorectal cancer Rectal cancer Survival skills Survival after airplane accidents, shipwrecks, etc Tumor spread Spread of cancer Dissemination of cancer Tumor metastasis Tumor dissemination Metastatic cancer Metastases Cancer--Dissemination Neoplasm metastasis Cancer metastasis Cancer--Metastasis Days of the week Colon cancer Colorectal cancer Drug therapy Pharmacotherapy Older persons Older adults Seniors (Older people) Elderly people Old people Senior citizens Aging people Aged illnessCiter ce document
Y. Seium et al., « Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study », Serveur académique Lausannois, ID : 10.1093/annonc/mdi154
Métriques
Partage / Export
Résumé
BACKGROUND: A phase I-II multicenter trial was conducted to define the maximal tolerated dose and describe the activity of an OCFL combination using oxaliplatin (OHP), irinotecan (CPT-11) and 5-fluorouracil (FU)/leucovorin (LV) in metastatic colorectal cancer (CRC). PATIENTS AND METHODS: CRC patients not pretreated with palliative chemotherapy, with performance status < or =1 and adequate haematological, kidney and liver function, were eligible. Treatment consisted in weekly 24-h infusion 5-FU (2300 mg/m(2))/LV (30 mg) and alternating OHP (70-85 mg/m(2), days 1 and 15) and CPT-11 (80-140 mg/m(2), days 8 and 22) repeated every 5 weeks. OHP and CPT-11 were escalated in cohorts of three to six patients. RESULTS: Thirty patients received a median of five cycles. Dose-limiting toxicity occurred at dose level 3, and the recommended dose was OHP 70 mg/m(2), CPT-11 100 mg/m(2), LV 30 mg and 5-FU 2300 mg/m(2)/24 h. Grade > or =3 toxicities were diarrhea 23%, neutropenia 20%, fatigue 7%, and neurologic 7%. Two febrile neutropenia episodes (one fatal) were recorded. Among 28 patients with measurable disease (90%), we observed two complete and 20 partial responses; overall RR was 78% (95% CI, 59% to 92%). Median time to progression and overall survival were 9.5 and 25.4 months, respectively. Seven patients underwent liver metastases resection. CONCLUSION: OCFL is an overall well tolerated regimen with very high efficacy, which makes it most suitable for tumour control before surgery of metastatic disease.